 Jayashree Kalpathy-Cramer
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 38 | 2025 | 279 | 5.850 |
Why?
| | Retinopathy of Prematurity | 34 | 2024 | 142 | 5.800 |
Why?
| | Image Processing, Computer-Assisted | 22 | 2025 | 752 | 3.250 |
Why?
| | Brain Neoplasms | 23 | 2024 | 1238 | 3.180 |
Why?
| | Glioblastoma | 15 | 2024 | 345 | 3.170 |
Why?
| | Algorithms | 38 | 2024 | 1704 | 2.500 |
Why?
| | Diagnostic Imaging | 19 | 2024 | 332 | 2.240 |
Why?
| | Machine Learning | 21 | 2024 | 493 | 2.230 |
Why?
| | Radiology | 10 | 2024 | 180 | 1.940 |
Why?
| | Natural Language Processing | 7 | 2023 | 95 | 1.910 |
Why?
| | Magnetic Resonance Imaging | 41 | 2024 | 3566 | 1.910 |
Why?
| | Information Storage and Retrieval | 8 | 2015 | 118 | 1.750 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2025 | 257 | 1.730 |
Why?
| | Neuroimaging | 7 | 2022 | 259 | 1.580 |
Why?
| | Glioma | 8 | 2022 | 395 | 1.470 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2016 | 130 | 1.310 |
Why?
| | Image Interpretation, Computer-Assisted | 13 | 2025 | 267 | 1.240 |
Why?
| | Papillomavirus Infections | 5 | 2025 | 325 | 1.150 |
Why?
| | Software | 10 | 2024 | 665 | 1.100 |
Why?
| | Optic Disk | 2 | 2025 | 45 | 1.010 |
Why?
| | Humans | 158 | 2025 | 137585 | 0.970 |
Why?
| | Glaucoma | 2 | 2025 | 237 | 0.920 |
Why?
| | Tomography, X-Ray Computed | 15 | 2023 | 2691 | 0.910 |
Why?
| | Severity of Illness Index | 9 | 2024 | 2828 | 0.890 |
Why?
| | ROC Curve | 15 | 2024 | 554 | 0.890 |
Why?
| | Telemedicine | 7 | 2023 | 862 | 0.880 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 213 | 0.870 |
Why?
| | Reproducibility of Results | 28 | 2025 | 3284 | 0.850 |
Why?
| | Ophthalmology | 5 | 2023 | 86 | 0.810 |
Why?
| | Radiology Information Systems | 4 | 2022 | 30 | 0.800 |
Why?
| | Solitary Pulmonary Nodule | 3 | 2021 | 22 | 0.800 |
Why?
| | Privacy | 1 | 2023 | 42 | 0.800 |
Why?
| | Retina | 6 | 2023 | 298 | 0.790 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2253 | 0.790 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2018 | 40 | 0.780 |
Why?
| | Infant, Newborn | 34 | 2024 | 6079 | 0.740 |
Why?
| | Radiologists | 4 | 2024 | 51 | 0.730 |
Why?
| | Ophthalmoscopy | 8 | 2024 | 36 | 0.730 |
Why?
| | Gestational Age | 17 | 2024 | 910 | 0.690 |
Why?
| | Sensitivity and Specificity | 14 | 2024 | 1946 | 0.670 |
Why?
| | Crowdsourcing | 1 | 2020 | 17 | 0.670 |
Why?
| | Fundus Oculi | 5 | 2025 | 65 | 0.660 |
Why?
| | Retinal Vessels | 6 | 2024 | 69 | 0.640 |
Why?
| | Medicine | 1 | 2021 | 121 | 0.640 |
Why?
| | Breast Density | 3 | 2024 | 6 | 0.620 |
Why?
| | Mammography | 4 | 2024 | 154 | 0.600 |
Why?
| | Stroke | 3 | 2023 | 1120 | 0.590 |
Why?
| | Retrospective Studies | 26 | 2025 | 15657 | 0.560 |
Why?
| | Retinal Vein | 4 | 2021 | 13 | 0.560 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2017 | 59 | 0.550 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 108 | 0.510 |
Why?
| | Lung Neoplasms | 5 | 2021 | 2526 | 0.500 |
Why?
| | Tumor Burden | 4 | 2023 | 309 | 0.500 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 97 | 0.490 |
Why?
| | Databases, Factual | 8 | 2021 | 1357 | 0.490 |
Why?
| | Quinolines | 1 | 2016 | 178 | 0.470 |
Why?
| | Gallbladder Neoplasms | 3 | 2011 | 23 | 0.470 |
Why?
| | Peripheral Arterial Disease | 4 | 2023 | 475 | 0.470 |
Why?
| | Female | 56 | 2025 | 73304 | 0.470 |
Why?
| | Radiography, Thoracic | 5 | 2022 | 167 | 0.460 |
Why?
| | Pattern Recognition, Automated | 5 | 2023 | 73 | 0.460 |
Why?
| | Prostatic Neoplasms | 5 | 2024 | 1043 | 0.460 |
Why?
| | Benchmarking | 6 | 2024 | 186 | 0.450 |
Why?
| | Cervix Uteri | 2 | 2025 | 48 | 0.440 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2025 | 42 | 0.440 |
Why?
| | Subtraction Technique | 1 | 2014 | 23 | 0.440 |
Why?
| | Delivery of Health Care | 1 | 2021 | 951 | 0.440 |
Why?
| | Photography | 6 | 2021 | 96 | 0.430 |
Why?
| | Radiation Oncology | 2 | 2014 | 82 | 0.430 |
Why?
| | Chemoradiotherapy | 6 | 2018 | 225 | 0.430 |
Why?
| | Early Detection of Cancer | 5 | 2025 | 447 | 0.430 |
Why?
| | Retinal Artery | 3 | 2021 | 17 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1079 | 0.430 |
Why?
| | Vocabulary, Controlled | 1 | 2014 | 47 | 0.430 |
Why?
| | White Matter | 3 | 2023 | 145 | 0.420 |
Why?
| | Phantoms, Imaging | 7 | 2023 | 152 | 0.410 |
Why?
| | Multimodal Imaging | 1 | 2014 | 113 | 0.400 |
Why?
| | Male | 51 | 2025 | 67762 | 0.400 |
Why?
| | Datasets as Topic | 5 | 2021 | 121 | 0.380 |
Why?
| | Middle Aged | 31 | 2025 | 33479 | 0.370 |
Why?
| | Survival Analysis | 4 | 2016 | 1325 | 0.370 |
Why?
| | Aged | 29 | 2025 | 23961 | 0.370 |
Why?
| | Cerebral Blood Volume | 3 | 2020 | 5 | 0.360 |
Why?
| | Radiotherapy, Conformal | 1 | 2011 | 70 | 0.360 |
Why?
| | Contrast Media | 9 | 2020 | 467 | 0.360 |
Why?
| | Internet | 2 | 2014 | 655 | 0.360 |
Why?
| | Mass Screening | 4 | 2025 | 1287 | 0.360 |
Why?
| | Clinical Competence | 2 | 2016 | 1118 | 0.350 |
Why?
| | Adrenoleukodystrophy | 2 | 2023 | 9 | 0.340 |
Why?
| | Brain | 8 | 2021 | 2668 | 0.340 |
Why?
| | Proportional Hazards Models | 4 | 2011 | 1266 | 0.340 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2023 | 110 | 0.330 |
Why?
| | Precision Medicine | 3 | 2024 | 429 | 0.330 |
Why?
| | Medical Informatics | 4 | 2020 | 101 | 0.320 |
Why?
| | Neoplasms | 7 | 2024 | 2671 | 0.320 |
Why?
| | Head and Neck Neoplasms | 5 | 2020 | 606 | 0.300 |
Why?
| | Database Management Systems | 1 | 2008 | 51 | 0.290 |
Why?
| | Endovascular Procedures | 2 | 2023 | 312 | 0.290 |
Why?
| | User-Computer Interface | 4 | 2015 | 159 | 0.290 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 220 | 0.280 |
Why?
| | Automation | 5 | 2020 | 95 | 0.280 |
Why?
| | Infant, Premature | 9 | 2024 | 574 | 0.280 |
Why?
| | Observer Variation | 4 | 2024 | 343 | 0.270 |
Why?
| | Lung | 6 | 2022 | 4060 | 0.270 |
Why?
| | Prognosis | 9 | 2024 | 4030 | 0.260 |
Why?
| | Adult | 26 | 2025 | 37929 | 0.260 |
Why?
| | Radiography | 5 | 2022 | 822 | 0.250 |
Why?
| | Neonatal Screening | 4 | 2023 | 169 | 0.240 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2018 | 153 | 0.240 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2007 | 228 | 0.240 |
Why?
| | Rectal Neoplasms | 2 | 2021 | 149 | 0.240 |
Why?
| | Predictive Value of Tests | 5 | 2025 | 2031 | 0.230 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2129 | 0.230 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2015 | 63 | 0.230 |
Why?
| | Reference Standards | 7 | 2021 | 186 | 0.220 |
Why?
| | Neoplasm Grading | 3 | 2024 | 307 | 0.220 |
Why?
| | Adenocarcinoma in Situ | 1 | 2023 | 1 | 0.220 |
Why?
| | Forecasting | 3 | 2019 | 389 | 0.210 |
Why?
| | Postoperative Care | 2 | 2019 | 261 | 0.210 |
Why?
| | Statistics as Topic | 2 | 2014 | 307 | 0.200 |
Why?
| | Ranibizumab | 1 | 2023 | 20 | 0.200 |
Why?
| | Imaging, Three-Dimensional | 4 | 2023 | 580 | 0.200 |
Why?
| | Oxygen | 2 | 2021 | 931 | 0.200 |
Why?
| | Macular Degeneration | 1 | 2024 | 164 | 0.200 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2016 | 142 | 0.200 |
Why?
| | Biomedical Research | 3 | 2024 | 692 | 0.200 |
Why?
| | Neovascularization, Pathologic | 3 | 2024 | 301 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 2 | 2021 | 89 | 0.200 |
Why?
| | Documentation | 2 | 2015 | 194 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2023 | 70 | 0.190 |
Why?
| | Computer Communication Networks | 2 | 2020 | 33 | 0.190 |
Why?
| | Quality Assurance, Health Care | 2 | 2014 | 322 | 0.190 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 81 | 0.180 |
Why?
| | Infant | 11 | 2024 | 9465 | 0.180 |
Why?
| | Diverticulitis | 1 | 2021 | 8 | 0.180 |
Why?
| | Patient-Specific Modeling | 2 | 2024 | 41 | 0.180 |
Why?
| | Cohort Studies | 6 | 2022 | 5742 | 0.180 |
Why?
| | Biomarkers | 4 | 2018 | 4149 | 0.180 |
Why?
| | Hospital Units | 1 | 2021 | 29 | 0.180 |
Why?
| | Racism | 1 | 2023 | 135 | 0.170 |
Why?
| | Musculoskeletal System | 1 | 2021 | 48 | 0.170 |
Why?
| | Intestinal Obstruction | 1 | 2021 | 51 | 0.170 |
Why?
| | India | 1 | 2021 | 195 | 0.170 |
Why?
| | Dacarbazine | 3 | 2015 | 98 | 0.170 |
Why?
| | Tibial Meniscus Injuries | 1 | 2021 | 48 | 0.170 |
Why?
| | Perfusion Imaging | 1 | 2020 | 58 | 0.170 |
Why?
| | Microcirculation | 2 | 2017 | 149 | 0.170 |
Why?
| | Radiometry | 1 | 2020 | 50 | 0.160 |
Why?
| | Health Information Exchange | 1 | 2020 | 23 | 0.160 |
Why?
| | Hyperemia | 1 | 2020 | 49 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2022 | 152 | 0.160 |
Why?
| | Medical Records Systems, Computerized | 2 | 2013 | 96 | 0.160 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1276 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2023 | 338 | 0.160 |
Why?
| | Medulloblastoma | 1 | 2022 | 193 | 0.160 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2017 | 145 | 0.160 |
Why?
| | Lung Injury | 1 | 2022 | 219 | 0.160 |
Why?
| | Area Under Curve | 4 | 2021 | 314 | 0.160 |
Why?
| | Brain Diseases | 1 | 2021 | 141 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 98 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 622 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2015 | 683 | 0.160 |
Why?
| | Appendicitis | 1 | 2021 | 130 | 0.160 |
Why?
| | Low Back Pain | 1 | 2021 | 108 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 545 | 0.160 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2018 | 73 | 0.150 |
Why?
| | Aneurysm, Ruptured | 1 | 2019 | 35 | 0.150 |
Why?
| | Capillary Permeability | 1 | 2019 | 145 | 0.150 |
Why?
| | Age Determination by Skeleton | 1 | 2018 | 18 | 0.150 |
Why?
| | Blood-Brain Barrier | 2 | 2017 | 138 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.150 |
Why?
| | Models, Biological | 4 | 2024 | 1783 | 0.150 |
Why?
| | Risk Factors | 8 | 2023 | 10388 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 804 | 0.150 |
Why?
| | Linear Models | 1 | 2021 | 849 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 258 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2018 | 39 | 0.150 |
Why?
| | Intracranial Aneurysm | 1 | 2019 | 97 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 238 | 0.140 |
Why?
| | Arteries | 2 | 2019 | 269 | 0.140 |
Why?
| | Medical Record Linkage | 1 | 2018 | 65 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1692 | 0.140 |
Why?
| | Prospective Studies | 7 | 2023 | 7604 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 318 | 0.140 |
Why?
| | Treatment Outcome | 7 | 2023 | 10811 | 0.140 |
Why?
| | Bayes Theorem | 2 | 2016 | 405 | 0.140 |
Why?
| | Polysaccharides, Bacterial | 1 | 2017 | 70 | 0.140 |
Why?
| | Gadolinium | 1 | 2017 | 82 | 0.140 |
Why?
| | Preoperative Period | 1 | 2017 | 129 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1483 | 0.140 |
Why?
| | Gray Matter | 1 | 2018 | 80 | 0.130 |
Why?
| | Patient Readmission | 1 | 2022 | 697 | 0.130 |
Why?
| | Chronic Pain | 1 | 2021 | 262 | 0.130 |
Why?
| | Computer Simulation | 5 | 2024 | 978 | 0.130 |
Why?
| | North America | 3 | 2024 | 313 | 0.130 |
Why?
| | Skin Diseases, Genetic | 1 | 2016 | 12 | 0.130 |
Why?
| | Pharyngeal Muscles | 1 | 2016 | 5 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2016 | 21 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 187 | 0.120 |
Why?
| | SEER Program | 3 | 2011 | 227 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 2 | 2016 | 229 | 0.120 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2020 | 49 | 0.120 |
Why?
| | Blood Volume Determination | 1 | 2015 | 5 | 0.120 |
Why?
| | Vascular Malformations | 1 | 2016 | 52 | 0.120 |
Why?
| | Risk Assessment | 4 | 2025 | 3457 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 815 | 0.120 |
Why?
| | Liver Cirrhosis | 1 | 2017 | 316 | 0.120 |
Why?
| | Positron-Emission Tomography | 4 | 2021 | 294 | 0.120 |
Why?
| | Cranial Irradiation | 1 | 2015 | 70 | 0.120 |
Why?
| | Fibrosis | 1 | 2017 | 552 | 0.110 |
Why?
| | Physical Phenomena | 1 | 2014 | 13 | 0.110 |
Why?
| | Organs at Risk | 1 | 2014 | 32 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2018 | 7635 | 0.110 |
Why?
| | Societies, Medical | 3 | 2024 | 820 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2016 | 145 | 0.110 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2844 | 0.110 |
Why?
| | Brachial Plexus | 1 | 2014 | 29 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 674 | 0.110 |
Why?
| | Birth Weight | 3 | 2023 | 516 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 816 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2011 | 43 | 0.110 |
Why?
| | Deglutition Disorders | 1 | 2016 | 143 | 0.110 |
Why?
| | Joint Instability | 1 | 2016 | 167 | 0.110 |
Why?
| | Mutation | 3 | 2024 | 3958 | 0.100 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 66 | 0.100 |
Why?
| | Arteriovenous Malformations | 1 | 2013 | 27 | 0.100 |
Why?
| | Bias | 3 | 2024 | 218 | 0.100 |
Why?
| | Computer Literacy | 1 | 2013 | 5 | 0.100 |
Why?
| | Health Information Systems | 1 | 2013 | 17 | 0.100 |
Why?
| | Young Adult | 7 | 2018 | 13209 | 0.100 |
Why?
| | Terminology as Topic | 1 | 2014 | 216 | 0.100 |
Why?
| | Survival Rate | 3 | 2018 | 1972 | 0.100 |
Why?
| | Otorhinolaryngologic Neoplasms | 1 | 2011 | 2 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2014 | 956 | 0.090 |
Why?
| | Nomograms | 1 | 2011 | 54 | 0.090 |
Why?
| | Workload | 1 | 2013 | 167 | 0.090 |
Why?
| | Research Design | 2 | 2014 | 1139 | 0.090 |
Why?
| | Child | 8 | 2024 | 21935 | 0.080 |
Why?
| | Support Vector Machine | 2 | 2021 | 38 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1724 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2069 | 0.080 |
Why?
| | Periodicals as Topic | 1 | 2012 | 211 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2023 | 125 | 0.080 |
Why?
| | Liver | 1 | 2017 | 1943 | 0.080 |
Why?
| | Oregon | 1 | 2008 | 74 | 0.080 |
Why?
| | United States | 5 | 2024 | 14841 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2057 | 0.070 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.070 |
Why?
| | Lower Extremity | 2 | 2023 | 427 | 0.070 |
Why?
| | MEDLINE | 1 | 2008 | 21 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5131 | 0.070 |
Why?
| | Dilatation, Pathologic | 2 | 2018 | 62 | 0.070 |
Why?
| | Breast | 2 | 2019 | 151 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2015 | 1069 | 0.070 |
Why?
| | Monte Carlo Method | 2 | 2017 | 148 | 0.060 |
Why?
| | Cluster Analysis | 1 | 2007 | 499 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2019 | 271 | 0.060 |
Why?
| | Tanzania | 1 | 2025 | 58 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2025 | 57 | 0.060 |
Why?
| | Critical Illness | 2 | 2021 | 811 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2024 | 78 | 0.060 |
Why?
| | Netherlands | 1 | 2024 | 88 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 910 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 257 | 0.050 |
Why?
| | Kinetics | 2 | 2019 | 1670 | 0.050 |
Why?
| | Colposcopy | 1 | 2023 | 18 | 0.050 |
Why?
| | Brain Infarction | 1 | 2023 | 23 | 0.050 |
Why?
| | DNA, Viral | 1 | 2025 | 364 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 65 | 0.050 |
Why?
| | Models, Theoretical | 2 | 2021 | 578 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 28 | 0.050 |
Why?
| | Data Curation | 1 | 2022 | 17 | 0.050 |
Why?
| | DNA Helicases | 1 | 2024 | 145 | 0.050 |
Why?
| | Smartphone | 1 | 2023 | 91 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2022 | 78 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5472 | 0.050 |
Why?
| | Quinazolines | 2 | 2013 | 251 | 0.050 |
Why?
| | Logistic Models | 2 | 2021 | 2074 | 0.050 |
Why?
| | Limb Salvage | 1 | 2022 | 57 | 0.050 |
Why?
| | Health Services | 1 | 2022 | 107 | 0.050 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2024 | 190 | 0.050 |
Why?
| | Vagina | 1 | 2024 | 187 | 0.050 |
Why?
| | Utilization Review | 1 | 2021 | 36 | 0.040 |
Why?
| | Receptors, GABA | 1 | 2021 | 14 | 0.040 |
Why?
| | Edema | 1 | 2022 | 130 | 0.040 |
Why?
| | Nepal | 1 | 2021 | 30 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 404 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2023 | 297 | 0.040 |
Why?
| | Massachusetts | 1 | 2021 | 172 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3556 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1050 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 242 | 0.040 |
Why?
| | Abdomen | 1 | 2021 | 125 | 0.040 |
Why?
| | Seizures | 1 | 2024 | 426 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1916 | 0.040 |
Why?
| | Incidence | 2 | 2020 | 2804 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 155 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 617 | 0.040 |
Why?
| | Ankle | 1 | 2020 | 60 | 0.040 |
Why?
| | Models, Statistical | 2 | 2016 | 669 | 0.040 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 28 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2023 | 406 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2757 | 0.040 |
Why?
| | Hand Bones | 1 | 2018 | 2 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 141 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2024 | 712 | 0.040 |
Why?
| | Risk | 1 | 2021 | 912 | 0.040 |
Why?
| | Arthroscopy | 1 | 2021 | 222 | 0.040 |
Why?
| | Bevacizumab | 1 | 2019 | 138 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 172 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 49 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 289 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 285 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 795 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2019 | 120 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 816 | 0.040 |
Why?
| | Hemizygote | 1 | 2017 | 5 | 0.040 |
Why?
| | Carbon Tetrachloride | 1 | 2017 | 13 | 0.040 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 189 | 0.040 |
Why?
| | Half-Life | 1 | 2017 | 164 | 0.030 |
Why?
| | Skull | 1 | 2018 | 139 | 0.030 |
Why?
| | Diffusion | 1 | 2017 | 116 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 161 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 389 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | Outpatients | 1 | 2021 | 396 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 89 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 596 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 332 | 0.030 |
Why?
| | Information Dissemination | 1 | 2019 | 218 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2016 | 67 | 0.030 |
Why?
| | Expert Systems | 1 | 2016 | 3 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 645 | 0.030 |
Why?
| | Prostate | 1 | 2017 | 175 | 0.030 |
Why?
| | Palate, Soft | 1 | 2016 | 15 | 0.030 |
Why?
| | Video Recording | 1 | 2017 | 180 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 788 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 141 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 180 | 0.030 |
Why?
| | Antineoplastic Protocols | 1 | 2015 | 1 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1719 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 240 | 0.030 |
Why?
| | Perfusion | 1 | 2016 | 213 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 86 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2016 | 56 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2017 | 243 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 268 | 0.030 |
Why?
| | Motion | 1 | 2015 | 99 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 686 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 79 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2014 | 37 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1622 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 739 | 0.030 |
Why?
| | Image Enhancement | 1 | 2015 | 190 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 17 | 0.030 |
Why?
| | Carcinoma | 1 | 2016 | 240 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 28 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2015 | 233 | 0.030 |
Why?
| | Child, Preschool | 2 | 2018 | 11074 | 0.030 |
Why?
| | Argentina | 1 | 2013 | 26 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 411 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 431 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2013 | 151 | 0.020 |
Why?
| | Adolescent | 3 | 2018 | 21513 | 0.020 |
Why?
| | Life Tables | 1 | 2011 | 20 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 234 | 0.020 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2011 | 12 | 0.020 |
Why?
| | Hemodynamics | 1 | 2016 | 1113 | 0.020 |
Why?
| | Smoking | 1 | 2019 | 1627 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 327 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 852 | 0.020 |
Why?
| | Time Factors | 1 | 2022 | 6828 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2199 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6763 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1040 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1062 | 0.020 |
Why?
| | Probability | 1 | 2011 | 304 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 470 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1710 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1295 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2011 | 352 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 889 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5647 | 0.020 |
Why?
| | PubMed | 1 | 2008 | 11 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 759 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4295 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1389 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1171 | 0.010 |
Why?
| | Internship and Residency | 1 | 2014 | 1147 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3295 | 0.010 |
Why?
| | Mice | 1 | 2017 | 17787 | 0.010 |
Why?
| | Animals | 1 | 2017 | 36940 | 0.010 |
Why?
|
|
Kalpathy-Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|